PepGen Raises $112.5M to Move EDO Therapies to Human Trials

PepGen Raises $112.5M to Move EDO Therapies to Human Trials

302597

PepGen Raises $112.5M to Move EDO Therapies to Human Trials

PepGen has raised funding totaling $112.5 million to advance toward the clinic its enhanced delivery oligonucleotide (EDO) lead programs in Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The funding round keeps PepGen on track to start Phase 1 clinical trials in 2022 for DMD, and in early 2023 for DM1. These trials will test the company’s lead EDO therapy candidates, which PepGen hopes will be able to correct the genetic cause of…

You must be logged in to read/download the full post.